Arvinas announced that Brad Margus, M.B.A., has stepped down from the company’s Board and Everett Cunningham has been appointed to join. Cunningham currently serves as Chief Commercial Officer at Exact Sciences and was previously President & CEO of GE Healthcare’s U.S. & Canada regions.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARVN:
- Arvinas Announces Changes to its Board of Directors
- Arvinas price target lowered to $72 from $88 at Citi
- Analysts Say These 2 ‘Strong Buy’ Stocks Are Their Top Picks for 2023
- Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
- Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update